CytomX Therapeutics Inc (CTMX) Expected to Post Quarterly Sales of $10.70 Million

Analysts expect that CytomX Therapeutics Inc (NASDAQ:CTMX) will report $10.70 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for CytomX Therapeutics’ earnings. The lowest sales estimate is $600,000.00 and the highest is $16.50 million. CytomX Therapeutics reported sales of $6.27 million in the same quarter last year, which indicates a positive year over year growth rate of 70.7%. The business is scheduled to announce its next earnings results on Thursday, March 1st.

According to Zacks, analysts expect that CytomX Therapeutics will report full-year sales of $10.70 million for the current fiscal year, with estimates ranging from $45.20 million to $61.00 million. For the next financial year, analysts forecast that the firm will post sales of $79.53 million per share, with estimates ranging from $60.00 million to $104.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.14). CytomX Therapeutics had a negative return on equity of 92.42% and a negative net margin of 113.64%.

A number of equities analysts have recently issued reports on CTMX shares. Citigroup started coverage on CytomX Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 15th. ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Cantor Fitzgerald started coverage on CytomX Therapeutics in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 target price for the company. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.78.

Shares of CytomX Therapeutics (CTMX) opened at $25.55 on Friday. CytomX Therapeutics has a 52-week low of $11.11 and a 52-week high of $25.84. The company has a market capitalization of $985.18, a P/E ratio of -16.07 and a beta of 0.47.

In related news, CEO Sean A. Mccarthy sold 14,342 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $19.86, for a total transaction of $284,832.12. Following the completion of the sale, the chief executive officer now directly owns 18,587 shares of the company’s stock, valued at approximately $369,137.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean A. Mccarthy sold 14,340 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.60, for a total value of $295,404.00. The disclosure for this sale can be found here. Insiders have sold a total of 70,760 shares of company stock valued at $1,533,840 over the last ninety days. Insiders own 4.70% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its holdings in CytomX Therapeutics by 1.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 292 shares in the last quarter. Legal & General Group Plc increased its holdings in CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,434 shares in the last quarter. Nationwide Fund Advisors increased its holdings in CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 4,622 shares in the last quarter. New York State Common Retirement Fund increased its holdings in CytomX Therapeutics by 18.6% during the 3rd quarter. New York State Common Retirement Fund now owns 36,900 shares of the biotechnology company’s stock valued at $670,000 after purchasing an additional 5,800 shares in the last quarter. Finally, Bank of Montreal Can acquired a new stake in CytomX Therapeutics during the 4th quarter valued at $124,000. 63.13% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/20/cytomx-therapeutics-inc-ctmx-expected-to-post-quarterly-sales-of-10-70-million-2.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply